Page 2 - Licence Application News Today

QX Resources Limited (ASX:QXR) confirms its intention to commence a formal application for a Mining Lease to advance development at the Companys Anthony Molybdenum (Mo) project in Central Queensland.

This article reveals how Pfizer’s bedfellow BioNTech –  in respect of the Pfizer BioNTech mRNA COVID-19 vaccine – is just as culpable.

/PRNewswire/ - NexGen Energy Ltd. ("NexGen" or the "Company") (TSX: NXE) (NYSE: NXE) (ASX: NXG) is pleased to announce another significant milestone in the...

Dublin, Aug. 19, 2022 (GLOBE NEWSWIRE) -- The "Narcolepsy Therapeutics Market - A Global and Country Level Analysis: Focus on Therapeutics, Indication,...

Press release content from Business Wire. The AP news staff was not involved in its creation.

Do you think you made a mistake, for example, in not including enough elderly people in your initial trial? because that caused some concern about whether your particular vaccine was, in the early days of this crisis, good at ensuring protection for older people, because you hadnt used many in your trials. in fact, we have the same proportion of older adults in our trials as all the other developers. but the specific issue here was at the time when we had our provisional application, we didnt ha...

MMO grants marine licence to marine development project following collaboration and joint working.

Application for Exploitation License expected in Q1/2022Initiation of feasibility work underwayInitiation of Environmental and Social Impact Assessment is...

That, as we developed the vaccine, the safety monitoring boards view was that we should recruit the older adults a little bit later in the trial. so by the time of that first licence application, they hadnt all had enough time to get the efficacy results around severe disease. so thats one reason. and of course, the other is that, particularly here in the uk, but certainly also in our large study in brazil, older adults are rather more cautious during the pandemic. and so they have had less expo...

Here was at the time when we had our provisional application, we didnt have enough cases of disease in older adults. and the reason for that is just that, as we developed the vaccine, the safety monitoring boards view was that we should recruit the older adults a little bit later in the trial. so by the time of that first licence application, they hadnt all had enough time to get the efficacy results around severe disease. so thats one reason. and of course, the other is that, particularly here ...